To kill two birds with one stone : targeting myeloid cells in cancers

Cancer progression is often accompanied by chronic inflammation and severe impairment of the immune system. In recent years, therapies eliciting tumor-specific immunity have resulted in striking tumor control and survival benefits in cancer patients. However, establishment of effective and durable immune responses is hampered by various tumor-dependent mechanisms. Besides the direct suppression mediated by tumor cells, a number of immune cell types, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), ‘M2-biased’ tumor-associated macrophages (TAMs) and regulatory dendritic cells, occur in the periphery and tumor microenvironment. These cells conduct potent inhibition of anti-tumor immunity and are associated with poor prognosis in patients. Studies included in this thesis aim to elucidate the molecular machinery that tumor cells utilize to induce suppressive functions from healthy myeloid cells (Study I, II and IV) and how the resulted suppressive myeloid cells could limit functions of T cells (Study I), natural killer (NK) cells (Study II) and differentiation of the immune-stimulating dendritic cells (DCs) (Study III). Finally, we tested the role of a myeloid-specific chemical inhibitor in antagonizing the induction of these suppressive myeloid cells in vitro. In a transgenic murine model developing highly aggressive spontaneous tumors, treatment with the inhibitor elicited robust control of established tumors and potentiated the anti-tumor effects of checkpoint blocking antibodies (Study IV). In summary, this thesis provides mechanistic insights for the induction of suppressive myeloid cells and demonstrates the therapeutic potential of targeting these cells for the treatment of solid tumors

Up-regulation of LCN2 in the anterior cingulate cortex contributes to neural injury-induced chronic pain

Chronic pain caused by disease or injury affects more than 30% of the general population. The molecular and cellular mechanisms underpinning the development of chronic pain remain unclear, resulting in scant effective treatments. Here, we combined electrophysiological recording, in vivo two-photon (2P) calcium imaging, fiber photometry, Western blotting, and chemogenetic methods to define a role for the secreted pro-inflammatory factor, Lipocalin-2 (LCN2), in chronic pain development in mice with spared nerve injury (SNI). We found that LCN2 expression was upregulated in the anterior cingulate cortex (ACC) at 14 days after SNI, resulting in hyperactivity of ACC glutamatergic neurons (ACCGlu) and pain sensitization. By contrast, suppressing LCN2 protein levels in the ACC with viral constructs or exogenous application of neutralizing antibodies leads to significant attenuation of chronic pain by preventing ACCGlu neuronal hyperactivity in SNI 2W mice. In addition, administering purified recombinant LCN2 protein in the ACC could induce pain sensitization by inducing ACCGlu neuronal hyperactivity in naïve mice. This study provides a mechanism by which LCN2-mediated hyperactivity of ACCGlu neurons contributes to pain sensitization, and reveals a new potential target for treating chronic pain

Cells and Fugu Response to Capsid of BFNNV Genotype

The nervous necrosis virus (NNV) of the BFNNV genotype is the causative agent of viral encephalopathy and retinopathy (VER) in cold water fishes. Similar to the RGNNV genotype, BFNNV is also considered a highly destructive virus. In the present study, the RNA2 of the BFNNV genotype was modified and expressed in the EPC cell line. The subcellular localization results showed that the capsid and N-terminal (1–414) were located in the nucleus, while the C-terminal (415–1014) of the capsid was located in the cytoplasm. Meanwhile, cell mortality obviously increased after expression of the capsid in EPC. EPC cells were transfected with pEGFP-CP and sampled at 12 h, 24 h and 48 h for transcriptome sequencing. There are 254, 2997 and 229 up-regulated genes and 387, 1611, and 649 down-regulated genes post-transfection, respectively. The ubiquitin-activating enzyme and ubiquitin-conjugating enzyme were up-regulated in the DEGs, indicating that cell death evoked by capsid transfection may be related to ubiquitination. The qPCR results showed that heat stock protein 70 (HSP70) is extremely up-regulated after expression of BFNNV capsid in EPC, and N-terminal is the key region to evoke the high expression. For further study, the immunoregulation of the capsid in fish pcDNA-3.1-CP was constructed and injected into the Takifugu rubripes muscle. pcDNA-3.1-CP can be detected in gills, muscle and head kidney, and lasted for more than 70 d post-injection. The transcripts of IgM and interferon inducible gene Mx were up-regulated after being immunized in different tissues, and immune factors, such as IFN-γ and C3, were also up-regulated in serum, while C4 was down-regulated one week after injection. It was suggested that pcDNA-3.1-CP can be a potential DNA vaccine in stimulating the immune system of T. rubripes; however, NNV challenge needs to be conducted in the following experiments

Cloning, Exogenous Expression and Function Analysis of Interferon–γ from <i>Gadus macrocephalus</i>

Interferon γ (IFN–γ) is now considered to be one of the key molecules in the regulation of innate and adaptive immunity. The function of IFN–γ is best described in humans, but less of IFN–γ in fish species has been described at protein level. In the present study, IFN–γ from Gadus macrocephalus (GmIFN–γ) has been examined in terms of bioinformatics, prokaryotic expression, yeast expression, antiviral activity and immune regulatory function. The cDNA of GmIFN–γ contains an open reading frame of 570 nucleotides, coding 189 amino acids. The mature protein contains a nuclear localization signal motif and an obvious IFN–γ signature sequence at the C-terminal. GmIFN–γ is very similar to that of Atlantic cod, with homology up to 89.89%, but less than 32% to other species. GmIFN–γ can be detected in the gills, spleen, intestine, brain and kidney. Interestingly, during early development, a strong signal of GmIFN–γ was not detected until 40 days post hatching. Prokaryotic expression plasmid pET–32a–GmIFN–γ was constructed, and the expression products in BL21 were confirmed by Mass Spectrometry. Meanwhile, the plasmid pGAPZA–GmIFN–γ with Myc tag was constructed and transmitted into Pichia pastoris yeast GS115, and the products were tested using Western blot. The purified GmIFN–γ from either BL21 or yeast has a strong antivirus (Spring viremia of carp virus) effect. The vector of pcDNA3.1–GmIFN–γ was expressed in EPC cell lines; high transcript levels of MHC class I chain-related protein A (MICA) gene were detected; and the exogenous GmIFN–γ protein could also induce MICA expression, indicating that GmIFN–γ could stimulate immune response. The yeast GS115 with GmIFN–γ protein, which is an inclusion body, was given to zebrafish orally, and the transcript of zebrafish IFN–γ was upregulated significantly; however, genes of the interferon type–I signal pathway were not well stimulated

Individual differences in dopamine level modulate the ego depletion effect.

Initial exertion of self-control impairs subsequent self-regulatory performance, which is referred to as the ego depletion effect. The current study examined how individual differences in dopamine level, as indexed by eye blink rate (EBR), would moderate ego depletion. An inverted-U-shaped relationship between EBR and subsequent self-regulatory performance was found when participants initially engaged in self-control but such relationship was absent in the control condition where there was no initial exertion, suggesting individuals with a medium dopamine level may be protected from the typical ego depletion effect. These findings are consistent with a cognitive explanation which considers ego depletion as a phenomenon similar to "switch costs" that would be neutralized by factors promoting flexible switching

Cloning and identification of CmCC-NB-ARC, a chrysanthemum white rust resistance gene

Chrysanthemum are important perennial commercial and ornamental flowers worldwide. Chrysanthemum white rust caused by the fungus Puccinia horiana is a destructive disease. Recent studies have aimed to identify sources of resistance to this disease, whereas genes related to the resistance to the fungus were rarely reported. In this study, we used highly resistant and susceptible chrysanthemum cultivars whose disease sensitivity was confirmed over years of observation. Using a conserved nucleotide binding site (NBS) domain sequence that is associated with resistance to rust in other plants as a query in a BLAST search against the chrysanthemum reference database, we identified the gene CHR00059759. There were eight consistent nonsynonymous mutations between the highly resistant and susceptible cultivars, five of which occurred in the NB-ARC conserved domain. The expression level of CmCC-NB-ARC increased and then decreased in the susceptible cultivar 'LZ08-61', whereas decreased and then increased in the resistant cultivar 'C029' in the eight time-points after inoculation with the fungus. In order to verify the gene function, we constructed an overexpression vector 35Spro:CmCC-NB-ARC and transformed into the susceptible cultivar 'Jinba'. Compared with 'Jinba', the relative expression levels of the gene in the transgenic plants increased significantly at 48h after inoculation. Compared with three overexpression lines, the diseased spots appeared in 'Jinba' at 15d after inoculation. Hence, we speculated the gene CmCC-NB-ARC conferred resistance to chrysanthemum white rust. This study provides insight into the mechanism of resistance to chrysanthemum white rust and might help inform the breeding of resistant cultivars

Interleukin-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy

Inflammatory mediators released by cancer cells promote the induction of immune suppression and tolerance in myeloid cells. Interleukin-1 receptor-associated kinase-3 (IRAK3) is a pseudokinase that inhibits IL-1/TLR signaling but its role in patients treated with immune checkpoint blockade (ICB) therapy remains unclear. Using RNAseq data from the IMvigor210 trial, we found that tumors with high IRAK3 expressions showed enriched anti-inflammatory pathways and worse clinical response to ICB therapy. Upon IRAK3 protein deletion with CRISPR/Cas9, primary human monocytes displayed altered global protein expression and phosphorylation in quantitative proteomics and released more pro-inflammatory cytokines in response to stimulation. Bone-marrow derived macrophages from an IRAK3 CRISPR knockout (KO) mouse model demonstrated a pro -inflammatory phenotype and enhanced sensitivity to TLR agonists, compared to wild-type cells. IRAK3 deficiency delayed the growth of carcinogen-induced and oncogene-driven murine cancer cells and induced enhanced activation in myeloid cells and T cells. Upon ICB treatment, IRAK3 KO mice showed enrichment of TCF1+PD-1+ stem-like memory CD8+ T cells and resulted in superior growth inhibition of immunologically cold tumors in vivo. Altogether, our study demonstrated a novel cancer-driven immune tolerance program controlled by IRAK3 in humans and mice and proposed its suitability as an immunotherapy target.De två första författarna delar förstaförfattarskapet.</p

Prognostic Value of Chromatin Structure Typing in Early-Stage Non-Small Cell Lung Cancer

(1) Background: Chromatin structure typing has been used for prognostic risk stratification among cancer survivors. This study aimed to ascertain the prognostic values of ploidy, nucleotyping, and tumor–stroma ratio (TSR) in predicting disease progression for patients with early-stage non-small cell lung cancer (NSCLC), and to explore whether patients with different nucleotyping profiles can benefit from adjuvant chemotherapy. (2) Methods: DNA ploidy, nucleotyping, and TSR were measured by chromatin structure typing analysis (Matrix Analyser, Room4, Kent, UK). Cox proportional hazard regression models were used to assess the relationships of DNA ploidy, nucleotyping, and TSR with a 5-year disease-free survival (DFS). (3) Results: among 154 early-stage NSCLC patients, 102 were non-diploid, 40 had chromatin heterogeneity, and 126 had a low stroma fraction, respectively. Univariable analysis suggested that non-diploidy was associated with a significantly lower 5-year DFS rate. After combining DNA ploidy and nucleotyping for risk stratification and adjusting for potential confounders, the DNA ploidy and nucleotyping (PN) high-risk group and PN medium-risk group had a 4- (95% CI: 1.497–8.754) and 3-fold (95% CI: 1.196–6.380) increase in the risk of disease progression or mortality within 5 years of follow-up, respectively, compared to the PN low-risk group. In PN high-risk patients, adjuvant therapy was associated with a significantly improved 5-year DFS (HR = 0.214, 95% CI: 0.048–0.957, p = 0.027). (4) Conclusions: the non-diploid DNA status and the combination of ploidy and nucleotyping can be useful prognostic indicators to predict long-term outcomes in early-stage NSCLC patients. Additionally, NSCLC patients with non-diploidy and chromatin homogenous status may benefit from adjuvant therapy